These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23968672)

  • 21. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada.
    Kratzer J; Cheng L; Allin S; Law MR
    Healthc Policy; 2015 May; 10(4):62-74. PubMed ID: 26142359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability in prescription medication coverage for children and youth across Canada: A scoping review.
    Ahmad A; Abbas M; Miregwa B; Holbrook AM
    Health Policy; 2022 Mar; 126(3):269-279. PubMed ID: 35140016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.
    Tadrous M; Martins D; Mamdani MM; Gomes T
    CMAJ Open; 2020; 8(2):E297-E303. PubMed ID: 32345708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addressing cost-related barriers to prescription drug use in Canada.
    Tang KL; Ghali WA; Manns BJ
    CMAJ; 2014 Mar; 186(4):276-80. PubMed ID: 24043654
    [No Abstract]   [Full Text] [Related]  

  • 33. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

  • 34. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.
    Kim SH; Ryu YJ; Cho NE; Kim AE; Chang J
    Clin Drug Investig; 2017 Oct; 37(10):957-963. PubMed ID: 28735450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription drug benefits: promising solutions.
    Goff VV
    Issue Brief (Inst Health Care Costs Solut); 2002; 1(4):1-16. PubMed ID: 12825600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

  • 38. Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings.
    O'Brady S; Gagnon MA; Cassels A
    Health Policy; 2015 Feb; 119(2):224-31. PubMed ID: 25498311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health benefits in 2014: stability in premiums and coverage for employer-sponsored plans.
    Claxton G; Rae M; Panchal N; Whitmore H; Damico A; Kenward K
    Health Aff (Millwood); 2014 Oct; 33(10):1851-60. PubMed ID: 25214470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.